Sarepta pays StrideBio $48M for preclinical gene therapies

People shaking hands across a desk that has computer and papers on it
A new deal furthers Sarepta's move into gene therapies and beyond Duchenne muscular dystrophy. (rawpixel/Pixabay)

Sarepta Therapeutics is set to pay $48 million upfront to work with StrideBio on gene therapies. The deal gives Sarepta exclusive licenses to four CNS targets, plus an option to pay a further $42.5 million to add another four targets to the deal.

In return for the initial outlay, Sarepta will secure the rights to gene therapies against Rett syndrome, Dravet syndrome, Angelman syndrome and Niemann-Pick. StrideBio will handle the development of the AAV capsid and all other IND-enabling R&D. Sarepta and StrideBio will then share early clinical development work for selected candidates.

Sarepta CEO Doug Ingram framed the division of responsibilities as a way for his company to “gain access to new technology and targets” without distracting it from its near-term priorities.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

StrideBio’s AAV capsids are the centerpiece of the technology covered by the deal. The capsids could set StrideBio apart from the growing pack of gene therapy biotechs. Notably, StrideBio is working on capsids capable of evading neutralizing antibodies, thereby enabling repeat dosing. Sarepta called out re-dosing as a focal point of its collaboration with StrideBio. 

By granting Sarepta rights to gene therapies based on the technology, StrideBio has positioned itself to receive “significant” but currently undisclosed milestones. The deal also grants StrideBio royalties and the chance to co-develop and co-commercialize one of the gene therapies. CRISPR Therapeutics and Takeda are among the companies that work with StrideBio in other contexts.

For Sarepta, the StrideBio deal furthers its move into gene therapies and beyond Duchenne muscular dystrophy, the indication in which it made its name. Over the past two years, Sarepta has teamed up with academic labs to work on treatments for Rett, cardiomyopathy and multiple sclerosis, while also partnering with Lysogene and Lacerta Therapeutics on Sanfilippo syndrome and Pompe disease.  

Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.